<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Advances in Current Biology</journal-id><journal-title-group><journal-title xml:lang="en">Advances in Current Biology</journal-title><trans-title-group xml:lang="ru"><trans-title>Успехи современной биологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0042-1324</issn><issn publication-format="electronic">3034-6347</issn><publisher><publisher-name xml:lang="en">The Russian Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">687227</article-id><article-id pub-id-type="doi">10.31857/S0042132425020012</article-id><article-id pub-id-type="edn">GCYTFZ</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Monoclonal antibodies to a variable fragment of the T cell receptor – at the service of science and medicine</article-title><trans-title-group xml:lang="ru"><trans-title>Моноклональные антитела к вариабельному фрагменту Т-клеточного рецептора – на службе у науки и клиники</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Khokhlov</surname><given-names>V. P.</given-names></name><name xml:lang="ru"><surname>Хохлов</surname><given-names>В. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>med9000@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Engelhardt Institute of Molecular Biology, Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">Институт молекулярной биологии им. В.А. Энгельгардта РАН</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2025</year></pub-date><volume>145</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>93</fpage><lpage>115</lpage><history><date date-type="received" iso-8601-date="2025-07-10"><day>10</day><month>07</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-07-10"><day>10</day><month>07</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Russian Academy of Sciences</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Российская академия наук</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Russian Academy of Sciences</copyright-holder><copyright-holder xml:lang="ru">Российская академия наук</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/0042-1324/article/view/687227">https://journals.eco-vector.com/0042-1324/article/view/687227</self-uri><abstract xml:lang="en"><p>This review summarizes recent progress in the engineering of monoclonal antibodies directed to a variable fragment of the T cell receptor with a given mode of action on the targeted subset of T lymphocytes. Since the unique T cell subsets are responsible for the development and outcome of many socially significant diseases the ability of monoclonal antibodies to deplete or expand pathogenetically important T cell families is of a grate interest in clinical practice. The review also discusses the role of the unique T cell families in the pathogenesis of a number of autoimmune and infectious diseases, which provides the prerequisites for the creation of highly effective targeted drugs based on monoclonal antibodies to a variable fragment of the T cell receptor.</p></abstract><trans-abstract xml:lang="ru"><p>Обобщен недавний прогресс в разработке моноклональных антител, направленных на вариабельный фрагмент Т-клеточного рецептора, с заданным способом воздействия на целевую субгруппу Т-лимфоцитов. Поскольку уникальные субгруппы Т-клеток ответственны за развитие и исход многих социально значимых заболеваний, способность моноклональных антител уничтожать или расширять патогенетически важные семейства Т-клеток представляет большой интерес в клинической практике. Также обсуждается роль уникальных семейств Т-клеток в патогенезе ряда аутоиммунных и инфекционных заболеваний, что создает предпосылки для разработки высокоэффективных таргетных препаратов на основе моноклональных антител к вариабельному фрагменту Т-клеточного рецептора.</p></trans-abstract><kwd-group xml:lang="en"><kwd>monoclonal antibody</kwd><kwd>T-cell receptor</kwd><kwd>the α/β-chain variable region</kwd><kwd>the α-chain variable region of the T-cell</kwd><kwd>the β-chain variable region of the T-cell receptor</kwd><kwd>complement-dependent cytotoxicity</kwd><kwd>antibody-dependent cellular cytotoxicity</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>моноклональное антитело</kwd><kwd>Т-клеточный рецептор</kwd><kwd>вариабельный фрагмент альфа/бета-цепи</kwd><kwd>комплемент-зависимая цитотоксичность</kwd><kwd>антитело-зависимая клеточная цитотоксичность</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Abe J., Kotzin B., Jujo K. et al. Selective expansion of T cells expressing T-cell receptor variable regions Vβ2 and Vβ8 in Kawasaki disease // PNAS USA. 1992. V. 89 (9). P. 4066–4070.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Acuto O., Fabbi M., Smart J. et al. Purification and NH2-terminal amino acid sequencing of the β subunit of a human T-cell antigen receptor // PNAS USA. 1984. V. 81 (12). P. 3851–3855.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Acuto O., Campen T.J., Royer H.D. et al. Molecular analysis of T cell receptor (Ti) variable region (V) gene expression. Evidence that a single Ti beta V gene family can be used in formation of V domains on phenotypically and functionally diverse T cell populations // J. Exp. Med. 1985. V. 161 (6). P. 1326–1343.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Ali M., Nelson A., Lopez A., Sack D. Updated global burden of cholera in endemic countries // PLoS Negl. Trop. Dis. 2015. V. 9 (6). e0003832.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Alvarez-Lafuente R., Fernandez-Gutierrez B., Jover J. et al. Human parvovirus B19, varicella zoster virus and human herpes virus 6 in temporal artery biopsy specimens of patients with giant cell arteritis: analysis with quantitative real time polymerase chain reaction // Ann. Rheum. Dis. 2005. V. 64 (5). P. 780–782.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Antibodies: a laboratory manual / Eds E. Harlow, D. Lane. N.Y.: Cold Spring Harbor Laboratory, 1988. 726 p.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Arden B., Clark S.P., Kabelitz D., Mak T.W. Human T-cell receptor variable gene segment families // Immunogenetics. 1995. V. 42 (6). P. 455–500.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Bhuiyan T., Rahman M., Trivedi S. et al. Mucosal associated invariant T (MAIT) cells are highly activated in duodenal tissue of humans with Vibrio cholera O1 infection: a preliminary report // PLoS Negl. Trop. Dis. 2022. V. 16 (5). e0010411.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Bigler R.D., Posnett D.N., Chiorazzi N. et al. Stimulation of the subset of normal resting T lymphocytes by a monoclonal antibody to a crossreactive determinant of the human T cell antigen receptor // J. Exp. Med. 1985. V. 161 (6). P. 1450–1463.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Bovay A., Zoete V., Dolton G. et al. T cell receptor alpha variable 12-2 bias in the immunodominant response to Yellow fever virus // Eur. J. Immunol. 2018. V. 48 (2). P. 258–272.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Bowerman N., Falta M., Mack D. et al. Identification of multiple public TCR repertoires in chronic beryllium disease // J. Immunol. 2014. V. 192 (10). P. 4571–4580.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Brack A., Geisler A., Martinez-Taboada V. et al. Giant cell vasculitis is a T cell-dependent disease // Mol. Med. 1997. V. 3 (8). P. 530–543.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Britanova O., Lupyr K., Staroverov D. et al. Targeted depletion of TRBV9+ T cells as immunotherapy in a patient with ankylosing spondylitis // Nat. Med. 2023. V. 29. P. 2731–2736.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Cavallo S. Immune-mediated genesis of multiple sclerosis // J. Transl. Autoimmun. 2020. V. 3. 100039.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Chester K., Hawkins R. Clinical issues in antibody design // Tr. Biotechnol. 1995. V. 13 (8). P. 294–300.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Cogswell D., Gapin L., Tobin H. et al. MAIT cells: partners or enemies in cancer immunotherapy? // Cancers. 2021. V. 13 (7). 1502.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Constantinides M., Link V., Tamoutounour S. MAIT cells are imprinted by the microbiota in early life and promote tissue repair // Science. 2019. V. 366 (6464). eaax6624.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Coppieters K., Dotta F., Amirian N. et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type I diabetes patients // J. Exp. Med. 2012. V. 209 (1). P. 51–60.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Damelang T., Brinkhaus M., Osch T. et al. Impact of structural modifications of IgG antibodies on effector functions // Front. Immunol. 2024. V. 14. 1304365.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Desquenne-Clark L., Esch T., Otvos Jr.L., Heber-Katz E. T-cell receptor peptide immunization leads to enhanced and chronic experimental allergic encephalomyelitis // PNAS USA. 1991. V. 88 (16). P. 7219–7223.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Elliott P., Andersson B., Arbustini E. et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases // Eur. Heart J. 2008. V. 29 (2). P. 270–276.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Esfandiarei M., McManus B. Molecular biology and pathogenesis of viral myocarditis // Annu. Rev. Pathol. 2008. V. 3. P. 127–155.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Frimpong A., Ofori M., Degoot A. et al. Perturbations in the T cell receptor β repertoire during malaria infection in children: a preliminary study // Front. Immunol. 2022. V. 13. 971392.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Fukazawa R., Kobayashi J., Ayusawa M. et al. JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease // Circ. J. 2020. V. 84 (8). P. 1348–1407.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Greaves S., Atif S., Fontenot A. Adaptive immunity in pulmonary sarcoidosis and chronic beryllium disease // Front. Immunol. 2020. V. 11. 474.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Gregory G., Robinson T., Linklater S. et al. Global incidence, prevalence and mortality of type 1 diabetes in 2021 with projection to 2040: a modeling study // Lancet. 2022. V. 10 (10). P. 741–760.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Grunewald J., Eklund A. Löfgren’s syndrome: human leukocyte antigen strongly influences the disease course // Am. J. Respir. Crit. Care Med. 2009. V. 179 (4). P. 307–312.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Grunewald J., Janson C., Eklund A. et al. Restricted V alpha 2.3 gene usage by CD4+ T lymphocytes in bronchoalveolar lavage fluid from sarcoidosis patients correlates with HLA-DR3 // Eur. J. Immunol. 1992. V. 22 (1). P. 129–135.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Guittet L., de Boysson H., Cerasuolo D. et al. Whole-country and regional incidences of giant cell arteritis in French continental and overseas territories: a 7-year nationwide database analysis // ACR Open Rheumatol. 2022. V. 4 (9). P. 753–759.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Hackstein CP., Klenerman P. Emerging features of MAIT cells and other unconventional T cell populations in human viral disease and vaccination // Semin. Immunol. 2022. V. 61–64. 101661.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Hannum C., Kappler J., Trowbridge I. et al. Immunoglobulin-like nature of the α-chain of a human T-cell antigen/MHC receptor // Nature. 1984. V. 312 (5989). P. 65–67.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Haugeberg G., Bie R., Nordbø S. Temporal arteritis associated with Chlamydia pneumoniae DNA detected in an artery specimen // J. Rheumatol. 2001. V. 28 (7). P. 1738–1739.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Hsu J., Donahue R., Katragadda M. et al. A T cell receptor β chain-directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity // Sci. Transl. Med. 2023. V. 15 (724). eadi0258.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Ikuta K., Ogura T., Shimizu A., Honjo T. Low frequency of somatic mutation in β-chain variable region genes of human T cell receptors // PNAS USA. 1985. V. 82 (22). P. 7701–7705.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Isobe M., Amano K., Arimura Y. et al. JCS 2017 guideline on management of vasculitis syndrome – digest version // Circ. J. 2020. V. 84 (2). P. 299–359.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Jog N., McClain M., Heinlen L. et al. Epstein–Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model // J. Autoimmun. 2020. V. 106. 102332.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Kalinina A., Bruter A., Nesterenko L. et al. Generation of TCR α-transduced T cells for adoptive transfer therapy of salmonellosis in mice // STAR Protoc. 2021. V. 2 (1). 100368.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Kanagawa O. In vivo T cell tumor therapy with monoclonal antibody directed to the Vβ chain of T cell antigen receptor // J. Exp. Med. 1989. V. 170 (5). P. 1513–1519.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Kappler J., Kubo R., Haskins J. et al. The mouse T cell receptor: comparison of MHC-restricted receptors on two T cell hybridomas // Cell. 1983. V. 34 (3). P. 727–737.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Kaskow B., Baecher-Allan C. Effector T cells in multiple sclerosis // Cold Spring Harbor Perspect. Med. 2018. V. 8 (4). a029025.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Kaushansky N., Eisenstein M., Zilkha-Falb R., Ben-Nun A. The myelin-associated oligodendrocytic basic protein (MOBP) as a relevant primary target autoantigen in multiple sclerosis // Autoimmun. Rev. 2010. V. 9 (4). P. 233–236.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Kawakami Y., Eliyahu S., Delgado C.H. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor // PNAS USA. 1994. V. 91 (9). P. 3515–3519.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Keller A., Eckle S., Xu W. et al. Drugs and drug-like molecules can modulate the function of mucosal-associated invariant T cells // Nat. Immunol. 2017. V. 18. P. 402–411.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Kotzin B., Karuturi S., Chou Y. et al. Preferential T cell receptor beta-chain variable gene use in myelin basic protein-reactive T cell clones from patients with multiple sclerosis // PNAS USA. 1991. V. 88 (20). P. 9161–9165.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Kumar V., Tabibiazar R., Geysen H., Sercarz E. Immunodominant framework region 3 peptide from TCR Vβ8.2 chain controls murine experimental autoimmune encephalomyelitis // J. Immunol. 1995. V. 154 (4). P. 1941–1950.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Helmick C., Felson D., Lawrence R. et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States // Arthritis Rheum. 2008. V. 58 (1). P. 26–35.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Leeansyah E., Boulouis C., Kwa A., Sandberg J. Emerging role for MAIT cells in control of antimicrobial resistance // Tr. Microbiol. 2021. V. 29 (6). P. 504–516.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Lefranc M.-P., Lefranc G. T Cell Receptor FactsBook. San Diego, San Francisco, New York, Boston, London, Sydney, Tokyo: Acad. Press, 2001. 398 p.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Leng T., Akther H., Hackstein CP. et al. TCR and inflammatory signals tune human MAIT cells to exert specific tissue repair and effector functions // Cell Rep. 2019. V. 28 (12). P. 3077–3091.e5</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Li B., Li T., Pignon J.C. et al. Landscape of tumor-infiltrating T cell repertoire of human cancers // Nat. Genet. 2016. V. 48 (7). P. 725–732.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Liu R., Oldham R., Teal E. et al. Fc-engineering for modulated effector functions – improving antibodies for cancer treatment // Antibodies. 2020. V. 9 (4). 64.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Liu Z., Cort L., Eberwine R. et al. Prevention of type 1 diabetes in the rat with an allele-specific anti-T-cell receptor antibody // Diabetes. 2012. V. 61 (5). P. 1160–1168.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Loh L., Wang Z., Sant S. et al. Human mucosal-associated invariant T cells contribute to antiviral influenza immunity via IL-18-dependent activation // PNAS USA. 2016. V. 113 (36). P. 10133–10138.</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Lopez-Hoyos M., Bartolome-Pacheco M., Blanco R. et al. Selective T cell receptor decrease in peripheral blood T lymphocytes of patients with polymyalgia rheumatic and giant cell arteritis // Ann. Rheum. Dis. 2004. V. 63 (1). P. 54–60.</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Lu R.M., Hwang Y.C., Liu I.J. et al. Development of therapeutic antibodies for the treatment of diseases // J. Biomed. Sci. 2020. V. 27 (1). 1.</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Marrero I., Aguilera C., Hamm D. et al. High-throughput sequencing reveals restricted TCR Vβ usage and public TCRβ clonotypes among pancreatic lymph node memory CD4+ T cells and their involvement in autoimmune diabetes // Mol. Immunol. 2018. V. 74. P. 82–95.</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>May E., Dilphy N., Frauendorf E. et al. Conserved TCR beta chain usage in reactive arthritis; evidence for selection by a putative HLA-B-27-associated autoantigen // Tiss. Antigens. 2002. V. 60 (4). P. 299–308.</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Meermeier E., Harriff M., Karamooz E., Lewinsohn D. MAIT cells and microbial immunity // Immunol. Cell Biol. 2018. V. 96 (6). P. 607–617.</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Middleton D., Menchaca L., Rood H., Komerofsky R. New allele frequency database: http://www.allelefrequencies.net // Tiss. Antigens. 2003. V. 61. P. 403–407.</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Mitchell A., Alkanani A., McDaniel K. et al. T cell responses to hybrid insulin peptides prior to type I diabetes development // PNAS USA. 2021. V. 118 (6). e2019129118.</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Nakatsugawa M., Yamashita Y., Ochi T. et al. Specific roles of each TCR hemichain in generating functional chain-centric TCR // J. Immunol. 2015. V. 194 (7). P. 3487– 3500.</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Nakayama M., Michels A. Using the T cell receptor as a biomarker in type 1 diabetes // Front. Immunol. 2021. V. 12. 777788.</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Nakayama M., McDaniel K., Fitzgerald-Miller L. et al. Regulatory vs inflammatory cytokine T-cell responses to mutated insulin peptides in healthy and type I diabetic subjects // PNAS USA. 2015. V. 112 (14). P. 4429–4434.</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Nasonov E., Mazurov V., Lila A. et al. Effectiveness and safety of BCD-180, anti-TRBV9+ T-lymphocytes monoclonal antibody in patients with active radiographic axial spondyloarthritis: 36-week results of double-blind randomized placebo-controlled phase II clinical study ELEFTA // Rheumatol. Sci. Pract. 2024. V. 62 (1). P. 65–80.</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Newman L., Lloyd J., Daniloff E. The natural history of beryllium sensitization and chronic beryllium disease // Environ. Health Perspect. 1996. V. 104 (Suppl. 5). P. 937–943.</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Noutsias M., Rohde M., Göldner K. et al. Expression of functional T-cell markers and T-cell receptor Vbeta repertoire in endomyocardial biopsies from patients presenting with acute myocarditis and dilated cardiomyopathy // Eur. J. Heart Fail. 2011. V. 13 (6). P. 611–618.</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Oksenberg J., Panzara M., Begovich A. et al. Selection for T-cell receptor Vβ-Dβ-Jβ gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis // Nature. 1993. V. 362. P. 68–70.</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Owhashi M., Heber-Katz E. Protection from experimental allergic encephalomyelitis conferred by a monoclonal antibody directed against a shared idiotype on rat T cell receptors specific for myelin basic protein // J. Exp. Med. 1988. V. 168 (6). P. 2153–2164.</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Paul S., Pearlman A., Douglass J. et al. TCR beta chain-directed bispecific antibodies for the treatment of T-cell cancers // Sci. Transl. Med. 2021. V. 13 (584). eabd3595.</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Perez-Mazliah D., Langhorne J. CD4 T-cell subsets in malaria: TH1/TH2 revisited // Front. Immunol. 2015. V. 5. 671.</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Porcelli S., Yockey C., Brenner M., Balk S. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4–8– alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain // J. Exp. Med. 1993. V. 178 (1). P. 1–16.</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>Posnett D.N., Bigler R.D., Bushkin Y. et al. T cell antiidiotypic antibodies reveal differences between two human leukemias // J. Exp. Med. 1984. V. 160 (2). P. 494–505.</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>Rashu R., Ninkov M., Wardell C. et al. Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens // PLoS Pathog. 2023. V. 19 (6). e1011485.</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Richeldi L., Sorrentino R., Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium diseas // Science. 1993. V. 262 (5131). P. 242–244.</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>Roep B., Peakman M. Diabetogenic T lymphocytes in human type 1 diabetes // Curr. Opin. Immunol. 2011. V. 23 (6). P. 746–753.</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>Rowen L., Koop B.F., Hood L. The complete 685-kilobase DNA sequence of the human beta T cell receptor locus // Science. 1996. V. 272 (5269). P. 1755–1762.</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation>Rowley A., Baker S., Shulman S. et al. Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a “new” virus associated with Kawasaki disease // J. Infect. Dis. 2011. V. 203 (7). P. 1021–1030.</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation>Saltini C., Winestock K., Kirby M. et al. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells // N. Engl. J. Med. 1989. V. 320(17). P. 1103–1109.</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation>Samson M., Ly K., Tournier B. et al. Involvement and prognosis value of CD8+ T cells in giant cell arteritis // J. Autoimmun. 2016. V. 72. P. 73–83.</mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation>Schmidt J., Smail A., Roche B. et al. Incidence of severe infections and infection-related mortality during the course of giant cell arteritis: a multicenter, prospective, double-cohort study // Arthritis Rheumatol. 2016. V. 68 (6). P. 1477–1482.</mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation>Smith T., Maricic I., Ria F. et al. CD8alpha+ dendritic cells prime TCR-peptide-reactive regulatory CD4+FOXP3-T cells // Eur. J. Immunol. 2010. V. 40 (7). P. 1906–1915.</mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation>Tolle M. Mosquito-borne diseases // Curr. Probl. Pediatr. Adolesc. Health Care. 2009. V. 39 (4). P. 97–140.</mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation>Tran M., Faridi P., Lim J. et al. T cell receptor recognition of hybrid insulin peptides bound to HLA-Dq8 // Nat. Commun. 2021. V. 12 (1). P. 1–13.</mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation>Urban J., Kumar V., Kono D. et al. Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy // Cell. 1988. V. 54 (4). P. 577–592.</mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation>Vandenbark A., Hashim G., Offner H. Immunization with a synthetic T cell receptor V region peptide protects against experimental autoimmune encephalomyelitis // Nature. 1989. V. 341 (6242). P. 541–544.</mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation>Walker L., Tharmalingam H., Klenerman P. The rise and fall of MAIT cells with age // Scand. J. Immunol. 2014. V. 80 (6). P. 462–463.</mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation>Wang C.Y., Bushkin Y., Pica R. et al. Stimulation and expansion of a human T-cell subpopulation by a monoclonal antibody to T-cell receptor molecule // Hybridoma. 1986. V. 5 (3). P. 179–190.</mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation>Wei S., Charmley P., Robinson M.A., Concannon P. The extent of the human germline T-cell receptor V beta gene segment repertoire // Immunogenetics. 1994. V. 40 (1). P. 27–36.</mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation>Weyand C., Schönberger J., Oppitz U. et al. Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes // J. Exp. Med. 1994. V. 179 (3). P. 951–960.</mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation>Wilson R.K., Lai E., Concannon P. et al. Structure, organization and polymorphism of murine and human T-cell receptor alpha and beta chain gene families // Immunol. Rev. 1988. V. 101. P. 149–172.</mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation>Yong V. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS // Neurology. 2002. V. 59 (6). P. 802–808.</mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation>Zaller D., Osman G., Kanagawa O., Hood L. Prevention and treatment of murine experimental allergic encephalomyelitis with T cell receptor Vβ-specific antibodies // J. Exp. Med. 1990. V. 171 (6). P. 1943–1955.</mixed-citation></ref></ref-list></back></article>
